Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr;97(4):664-675.
doi: 10.1016/j.kint.2019.11.027. Epub 2019 Dec 24.

Role of direct oral anticoagulants in patients with kidney disease

Affiliations
Review

Role of direct oral anticoagulants in patients with kidney disease

Vimal K Derebail et al. Kidney Int. 2020 Apr.

Abstract

The anticoagulation field is experiencing a renaissance that began with regulatory approval of the direct thrombin inhibitor dabigatran, a direct oral anticoagulant (DOAC), in 2010. The DOAC medication class has rapidly evolved to include the additional approval of 4 direct factor Xa inhibitors. Commensurately, DOAC use has increased and collectively account for the majority of new anticoagulant prescriptions. Despite exclusion of patients with moderate-to-severe kidney disease from most pivotal DOAC trials, DOACs are increasingly used in this setting. An advantage of DOACs is similar or improved antithrombotic efficacy with less bleeding risk when compared with traditional agents. Several post hoc analyses, retrospective studies, claims data studies, and meta-analyses suggest that these benefits extend to patients with kidney disease. However, the lack of randomized controlled trial data in specific kidney disease settings, with their unique pathophysiology, should be a call to action for the kidney community to systematically study these agents, especially because early data suggest that DOACs may pose less risk of anticoagulant-related nephropathy than do vitamin K antagonists. Most DOACs are renally cleared and are significantly protein bound in circulation; thus, the pharmacokinetics of these drugs are influenced by reduced renal function and proteinuria. DOACs are susceptible to altered metabolism by P-glycoprotein inhibitors and inducers, including drugs commonly used for the management of kidney disease comorbidities. We summarize the currently available literature on DOAC use in kidney disease and illustrate knowledge gaps that represent important opportunities for prospective investigation.

Keywords: anticoagulation; atrial fibrillation; chronic kidney disease; dialysis; end-stage kidney disease; lupus nephritis; nephrotic syndrome; venous thromboembolism.

PubMed Disclaimer

Figures

Figure:
Figure:
Schematic Representation of Oral Anticoagulant Mechanisms of Action

References

    1. Shroff GR, Chang TI. Risk Stratification and Treatment of Coronary Disease in Chronic Kidney Disease and End-Stage Kidney Disease. Semin Nephrol 2018; 38: 582–599. - PubMed
    1. Christiansen CF, Schmidt M, Lamberg AL, et al. Kidney disease and risk of venous thromboembolism: a nationwide population-based case-control study. J Thromb Haemost 2014; 12: 1449–1454. - PubMed
    1. Kerlin BA, Smoyer WE, Tsai J, et al. Healthcare burden of venous thromboembolism in childhood chronic renal diseases. Pediatr Nephrol 2015; 30: 829–837. - PMC - PubMed
    1. Pavord S, Myers B. Bleeding and thrombotic complications of kidney disease. Blood Rev 2011; 25: 271–278. - PubMed
    1. Ghanta M, Kozicky M, Jim B. Pathophysiologic and treatment strategies for cardiovascular disease in end-stage renal disease and kidney transplantations. Cardiol Rev 2015; 23: 109–118. - PubMed

Publication types